Complement system play a crucial role in retinal homeostasis. Several proteomic studies have shown deposition of complement protein in ocular tissues from diabetic retinopathy, however, their exact involvement in pathogenesis of DR remains unclear.
control retinas, however, the expression of GFAP in diabetic retina was found to be slightly higher than that of control retinas (fig 6a and 6b ), suggesting the onset of gliosis in DM retinas. Increased expression of C3 and CD11b were observed in DM retina, while control retina had a relatively lower expression of these proteins ( Fig.7a and 7b ).
Further similar to the C3, an intense staining of CFH and its co-localized expression with CD11b positive cells in the retinal layers were observed in DM retina( Fig. 8a and 8b ). This suggests that upregulation of CFH in the diabetic retina could be a feedback mechanism of excess complement activation by microglial cells. Further, the IHC results identified distribution of CXCR4+ co-localizing with CD11b positive cells in DM retina, whereas in control retinas, the CXCR4 staining was negligibly low ( Fig. 9 ), suggestive of microglial activation and its enhanced chemotaxis under the diabetic stress. 10a) .
7.
Analysis of inflammation and microglial activation in vitreous samples by analyzing the level of sPECAM, IL-8 and IL-10.
The level of inflammation in vitreous samples were analysed by the quantitative estimation of proinflammatory markers such as sPECAM, IL-8 and also the estimation of anti-inflammatory marker IL-10. 14, p>0.05, non-significant) . In contrast to this, the level of antiinflammatory cytokine IL-10 was found to be significantly downregulated in PDR vitreous as compared to control (Control (n=8): 2.24±0.42, PDR (n=8): 0.57±0.09 p**<0.001) (Fig 10 b and 10c ). 
Discussion:
Diabetic retinopathy is a serious neuro-vascular complications of retina and involvement of complement pathway in DR progression is paid more attention after the identification of complement deposits in choriocapillaries of DR retina and reduced levels of complement pathway inhibitors in diabetic retina [16, 17] . A comprehensive study done by Garcia et al, identified a significant increase in 42kDa fragment of C3 and CFB in PDR vitreous and found it to correlate with the mRNA expression in diabetic retina [22] .
Additionally, various vitreous proteome studies in DR also identified the predominant deposition of complement proteins in PDR vitreous [20, 21, 26, 27] though exactly how complements are involved in PDR pathogenesis was not explored. Thus, here for the first time, we attempted a systematic evaluation of both alternative and classical pathwayof complement activation in PDR pathogenesis by analysing proteins of these two pathways in serum as well as in vitreous humor.The major rationale behind this comparison is that, if these proteins are contributed by blood retinal barrier breakdown in advance stages of the disease. Hence, we also checked for the systemic complement activation in serum from PDR, NPDR and no-DM subjects to make sure if complement dysregulation as seen in vitreous proteome in PDR is a localized effect and not an additive effect due to serum infiltration.
C3 is the central complement protein, where all the three complement pathways converge. The activation of complement pathway causes proteolytic fragmentation of C3 and these fragments can bind to the nearby tissues and enhance inflammatory process [28] . In our study cohort, no significant increase in total C3 or any of its activated fragments was seen among PDR and NPDR serum compared to control serum, while a significant increase in total C3 was observed in PDR vitreous. Though, there was no significant differences in number of activated C3 fragments in PDR vitreous compared to control, suggesting significant complement activation in control vitreous as well. This could also be attributed to homeostatic changes in retinal microenvironment in conditions of macular hole and retinal detachment cases that serve as controls for this experiment. However, a significant upregulation of C3bα'(110kDa) fragment was noted in the PDR vitreous. The reactive C3bα' is generated from 120kDa α -chain of C3 after the proteolytic removal of 10kDa C3a fragment and is the part of active C3b [29] . A significant increase in the level of C3bα'indicated for complement pathway activation in PDR vitreous. C1q and C4b are the proteins specific for classical pathway of complement activation and both these proteins identified an insignificant increase of C1q in PDR and NPDR serum and C1q and C4b in PDR vitreous. This suggested that classical complement pathway might not be playing asignificant role in PDR pathogenesis.
Further, we have looked into the alternative complement pathway by selecting CFB, a protein specific for alternative pathway that is required for the formation of C3 convertase (C3bBb) and activates the alternative pathway of complement [30] . Fragment Bb of factor B was found to be significantly downregulated in PDR vitreous which could be due to the formation of more C3bBb in PDR vitreous.
Next, we tested the levels of CFH, one of the major regulators of alternative complement pathway. CFH regulate alternative complement pathway in multiple steps such as competing with FB for C3b binding, also act as a co-factor for factor I to degrade C3b to C3bi [31] . We have expected a low level of CFH in PDR vitreous after observing the downregulation of free Bb in the PDR vitreous. But surprisingly, we found a significant upregulation of CFH gene expression in PDR vitreous. Several studies have shown that one of the binding sites of CFH for C3b is located in the C3bα' region [32] , and thus quite possibly the significant upregulation of CFH could be a feed-back mechanism for maintaining the level of C3bα'
in the PDR vitreous. Further the serum CFH levels on the other hand, showed a down-regulation of this protein in PDR cases compared to NPDR and control, suggesting thereby that the upregulation of CFH as seen in vitreous is a localized phenomenon.
Further immunohistochemistry experiments confirmed the CFH and C3 upregulation as seen in PDR vitreous, in the retinal tissues collected from diabetic donor eyes as compared to the control non diabeticdonor'sretina. Similar to the vitreous data, we found a concurrent deposition of C3 and CFH in the diabetic retina.To test further if this CFH and C3 overexpression as seen in retinal tissues from diabetic donor by microglial cells as seen in AMD and ROP conditions, we performed co-localization of CFH and C3 proteins with activated microglial specific marker CD11b. A significant amount of CFH expression was seen to localize with microglial cell that were present in the inner nuclear layers. We also noticed significant gliosis in the diabetic tissues as evident from the upregulation of GFAP protein in diabetic retina. However, it was microglial cells and not the macroglia that seemed to be the major source of complement proteins in diabetic retina. Further confirmation of the microglial activation as seen in PDR cases, was evident from the significant down regulation of IL-10 in the PDR vitreous samples while IL-8 was upregulated (though not statistically significant). IL-8 is a proinflammatory and IL-10 is an antiinflammatory cytokine secreted mainly by M1 and M2 microglia [33] . The down regulation of IL-10 and upregulation of IL-8 further confirmed activation of proinflammatory M1 phenotypes in PDR vitreous.
Microglial once activated are known to secrete the matrix metalloproteinases and this too was confirmed using. zymography that showed significantly increased level of MMP9 secretion in PDR vitreous [34] .
This further validated microglial activation in PDR vitreous. Alongside an increase in proinflammatory markers such as Il-8 and MMP9, a significant upregulation of sPECAM in the PDR vitreous, also indicated excessive inflammation in the PDR vitreous. This also suggests for an inflammatory environment in the PDR retina that could be a driving force for microglial activation. Microglial cells being the resident cells gets activated and move up from deep RGC layers towards photoreceptors.
Microglial activation was further evaluated in the diabetic retina using CXCR4, which is a chemokine receptorand known to be involved in astroglial activation and microglial signaling. Our IHC results identified an increased expression of these receptors in the inner retinal layers, suggesting microglial activation and its migration in diabetic retina.
Next, we correlated the increase in microglial cells with the mRNA expression of C3, CFH, THSB1, VEGF, TGFβ and CXCR4 in PBMNC isolated from PDR, NPDR and no-DM cases. Our gene expression data showed upregulation of C3 in PDR and NPDR cases and a concurrent downregulation of CFH. This was found to be consistent with the serum level C3 and CFH expression, where we found insignificant upregulation of C3 and downregulation of CFH in PDR and NPDR cases. Further the level of THSB1, a potent anti-angiogenic gene and also the activator of TGFβ1 [35] were evaluated and we found a significant downregulation of THSB1 in PDR and NPDR cases, simultaneously pro-inflammatory gene TGF β 1 also found to be downregulated. Our study also confirmed that THSB1 is a negative fluid phase regulator of alternative pathway of complement activation [36] .and therefore the downregulation of THSB1 further correlated with the complement pathway activation in DR.
In conclusion, our study provided a systematic analysis of classical and alternative complement pathway activation in PDR pathogenesis. We for the first time showed a significant upregulation of 110kDa
C3bα'and concurrent increase of CFH in PDR vitreous, and that this upregulation of complement cascade was localized to retina and not contributed by the blood retinal barrier breakdown which is common sight in advance PDR cases. Further, a correlation of increased Complement factor H expression and downregulation of Complement factor B with genetic changes in these genes could underscore the contribution of the alternate complement pathway in DR pathogenesis Lastly, our study suggested that activated microglia are the main source of alternative pathway of complement activation in PDR. In future, targeting microglial mediated complement activation could pave way for an effective therapeutic management of DR by the reducing underlying inflammation and abnormal angiogenesis. 
